Acute Graft-Versus-Host Disease Biomarkers Measured During Therapy Can Predict Treatment Outcomes: A Blood and Marrow Transplant Clinical Trials Network Study. Blood, 119, 3854-3860. presented at the 04/2012.. (2012).
Lymphocyte Phenotype During Therapy for Acute Graft Versus Host Disease: A Brief Report from BMT CTN 0302. Biol Blood Marrow Transplant, 19, 481-485. presented at the 03/2013. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/23247045. (2013).
Phase 3 Clinical trial of Steroids/Mycophenolate Mofetil vs Steroids/Placebo as Therapy for Acute GVHD: BMT CTN 0802. Blood, 124, 3221-3227. presented at the 11/2014. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/25170121. (2014).
Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: A grading algorithm versus blinded expert panel review. Biol Blood Marrow Transplant, 9, 512-8. presented at the 2003.. (2003).
Randomized, Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Idiopathic Pneumonia Syndrome After Allogeneic Stem Cell Transplantation: BMT CTN Protocol. Biol Blood Marrow Transplant, 20, 858-864. presented at the 06/2014. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/24607553. (2014).